New drug XTX202 tested in patients with advanced cancers

NCT ID NCT05052268

Completed Disease control Sponsor: Xilio Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XTX202
What this could lead to: If successful, XTX202 could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 95 participants, so results may not apply to all patients. Side effects and lack of tumor shrinkage are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma neoplasm non-small cell lung carcinoma ovarian cancer renal cell carcinoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Atlantic Health System/Morristown Medical Center

Morristown, New Jersey, 07960, United States
Carolina BioOncology Institute

Huntersville, North Carolina, 28078, United States
Georgetown University Medical Center

Washington D.C., District of Columbia, 20007, United States
HealthPartners Cancer Center at Regions Hospital

Saint Paul, Minnesota, 55101, United States
Hoag Memorial Hospital Presbyterian- Newport Beach

Newport Beach, California, 92663, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
Rutgers Cancer Institute of NJ

New Brunswick, New Jersey, 08903, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
The Ohio State University Wexner Medical Center James Cancer Hospital and Solove Research Institute

Columbus, Ohio, 43210, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
UPMC Hillman Cancer Center Pavilion

Pittsburgh, Pennsylvania, 15213, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.